Pharmalink strengthens senior management team

Appoints a new director of Regulatory Affairs and a new director of Business Development

Pharmalink, a Swedish specialist pharma company, has appointed Heather Cook as director of Regulatory Affairs and Marek Poszepczynski as director of Business Development.

Cook brings to Pharmalink more than 15 years of experience within the pharmaceutical industry, with a track record in global regulatory affairs and clinical development. Prior to joining Pharmalink, she was head of department for Regulatory Development Projects at Lundbeck. She was also Global Regulatory Affairs director, Oncology for AstraZeneca and held a number of other senior roles including scientific director for Neuroscience and Infection. She has worked in the UK, Canada, and Denmark and currently lives in Stockholm.

Poszepczynski joins Pharmalink after a career spanning 10 years and combining financial and business development experience. Hes was previously lead equity analyst at Handelsbanken covering European and Swedish biotechnology stocks. Prior to this he was vice president of Business Development at Karolinska Development.

Poszepczynski also spent six years at BioVitrum where he was director of Corporate Development.

You may also like

Regulatory

EMA issues positive opinion on Calliditas' orphan drug

Calliditas' application for orphan drug designation in the European Union (EU) for setanaxib in Alport syndrome has received a positive opinion from European Medicines Agency
Ingredients

Full details from Calliditas Therapeutics’ Phase 3 study released

Calliditas Therapeutics has announced publication in The Lancet of the full data from the Phase 3 NefIgArd Study with Nefecon delayed release capsules in adults with Primary IgA nephropathy
Regulatory

Calliditas receives fast track FDA designation for PBC candidate

The FDA program facilitates the expedited development and review of new drugs intended to treat serious or life-threatening conditions
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Subscribe now